CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2012 European Society for Medical Oncology
Oncology Conference Multimedia
View more videos >>
Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer
Dr. Markman Discusses the Phase III AURELIA Trial
Dr. Rotkowitz on Ipilimumab Plus Dacarbazine for Melanoma
Oncology Conference Articles
Tracking the Oncology Pipeline: Developments From ESMO
The latest research on several investigational cancer therapies was presented at the European Society for Medical Oncology 2012 Congress.
In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups
Regorafenib significantly delays disease progression in virtually all subgroups of patients with GIST in the second-line setting, and may even confer benefits when continued after progression.
Long-Term Data Show Significant Improvement in Survival With Ipilimumab in Melanoma
Nearly twice as many patients with metastatic melanoma who received a combination of ipilimumab and dacarbazine were alive after four years, suggesting that ipilimumab has long-term survival benefits.
One Year of Adjuvant Trastuzumab Remains Standard of Care
Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.
Bevacizumab Plus Chemotherapy Improves Response Rates and PFS in Platinum-Resistant Ovarian Cancer
An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.
No Survival Advantage for Ifosfamide Added to Doxorubicin in Advanced Soft Tissue Sarcoma
The addition of ifosfamide to doxorubicin in the treatment of advanced soft tissue sarcomas delayed disease progression but did not improve survival.
Pazopanib Another Front-Line Therapy Option for Metastatic Renal Cell Carcinoma
Pazopanib appears to be another good option for first-line therapy of metastatic renal cell carcinoma along with sunitinib.
Updated Data Show T-DM1 Improves Overall Survival in HER2-Positive Breast Cancer
An updated analysis of the phase III EMILIA trial showed that T-DM1 significantly extended survival in women with HER2-positive, unresectable, locally advanced or metastatic breast cancer.
Positive Results in ALK-Positive NSCLC With First ALK Inhibitor
Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.
Updated Regorafenib Survival Results Confirm Effectiveness
Patients with heavily pretreated metastatic colorectal cancer who received regorafenib experienced a sustained survival benefit across all prespecified subgroups.
Does Docetaxel Add Benefit to the Oral Fluoropyrimidine S-1 in Gastric Cancer?
Two analyses, two different conclusions in Asian START trial when docetaxel was added to S-1 for patients with previously untreated advanced or recurrent gastric cancer.
BRAF Inhibitor Plus MEK Inhibitor Encouraging in Metastatic Melanoma
Combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in patients with melanoma that had BRAF V600 mutations.
Gefitinib: Small Benefit as Second-Line Therapy in Esophageal Cancer
Gefitinib improved progression-free survival and some quality of life measures when used as second-line therapy for esophageal cancer.
FDA Approvals in Pediatric ALL and PNH, Japanese Approves Pembrolizumab in 5 Indications, and More
FDA Approves Cabozantinib for Advanced HCC
Treatment Goals in Refractory mCRC
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.